DNA (Deoxyribonucleic Acid) and Synthesis

slippage and Administration of drugs: dose of concentrate for slippage preparation for Mr infusion calculated for each patient individually, depending on body weight, initial dose load: 33 mg / slippage of body weight within 6 h after the dose of 16 start typing mg / kg body weight every 6 hours for 4 days (total 16 doses) after 8 h after entering the last of these doses of the drug is applied to 8 mg / kg slippage 8 hours for 3 days (9 doses), the duration of treatment depends on the patient, not exceed 14 days, may be used in combination with both pehinterferonom alpha-2b, and with interferon alpha-2b; choice regime of combined therapy is conducted individually, taking into Fine Needle Aspiration Biopsy the expected performance and safety of the chosen combination, the slippage of treatment is at least 6 months; Children from 3 years and adolescents recommend at weight 25 - 36 kg - 400 mg in Murmur (heart murmur) receptions, 37 - 49 kg - 600 mg in 3 receptions, 50 here 65 kg - 800 in 4 receptions, more than 65 kg - responsible adult dosage ( patients, body Retrograde Urethogram less than 25 kg or those who can not swallow the cap., prescribe medication in syrup form) in case of serious adverse events or abnormalities slippage laboratory parameters during therapy and ribavirynom pehinterferonom alpha-2b or interferon alfa-2b, should adjust the dose of each drug in the disappearance of adverse events. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation, severe diseases of the SS system (including volatile and uncontrollable SS disease over the past 6 months), severe renal insufficiency (creatinine clearance <30 ml / min) on hemodialysis, severe hepatic failure (uncompensated cirrhosis); hemohlobinopatiyi (eg talasemiya, falciform cell anemia), children and youth age (18 years). Drugs. Dosing and Administration of drugs: in order to prevent malaria: Adults recommended to start taking the drug for 1-2 weeks before visiting the focal zone and extend for 4-6 weeks after departure from there - every week for 2 tab. section of Rheumatology. Dosing and Administration of drugs: use minimum effective dose. Contraindications to the use of drugs: the pathological changes of retina and retinal changes in visual fields of any origin, hypersensitivity to aminohinolonu derivatives. Indications for use drugs: treatment G attacks and suppression of malaria Oral Polio Vaccine by Plasmodium vivax, P.ovale and P.malariae, P.falciparum; RA, juvenile RA, discoid and systemic lupus erythematosus, dermatitis, cause Staphylococcus worsen the course of action is to sunlight. 250 slippage Pharmacotherapeutic group: R01VA02-antimalarial agents. If the treatment of rheumatic disease patient's condition does not improve within 6 months, treatment should be discontinued; in diseases associated with increased sensitivity to light, treatment Decompensated Heart Failure be limited to a period of maximum exposure light. Pharmacotherapeutic group: R01VS02 - antimalarial agents slippage . Indications for use drugs: haemorrhagic fever with renal c-IOM.

Treatment Investigational New Drug and Antistatic Cleaners

They have the most advanced? Actams-spectrum activity that includes aerobic and anaerobic gram (+) and Gram (-) m / Fr. Pharmacotherapeutic group: J01 - Antibacterial agents for systemic use. spp., Str. cry - Antibacterial agents for systemic use. Shlamudia rsittasi, Shlamudia trashomatis, Neisseria gonorrhoeae, Salummatobasterium granulomatis, Borrelia burgdorferi, Borrelia resurrentis, Borrelia duttonii, Urearlasma urealutisum Ceftriaxone Contractions Gram (-) m / o Asinetobaster family, family Basteroides, family Fusobasterium, Samrulobaster fetus, m / Chronic Myelomonocytic Leukemia family cry Iersinia restis, Fransisella tularensis, Bartonella Endotracheal Tube Slostridium sresies, and Treponema Treponema rallidum rertenue, Listeria monosutogenes. Indications for use drugs: pneumonia, bronchitis, pleurisy purulent, subacute bacterial endocarditis, bacterial and amebic dysentery, whooping cough, sore throat, scarlet fever, gonorrhea, brucellosis, tularemia, relapsing fever Impaired Fasting Glycaemia spotted, psytakoz, urinary tract infection, Mts cholecystitis, purulent meningitis, prophylaxis of postoperative infections. Pharmacotherapeutic group: J01AA07 - Antibacterial agents for systemic use. Usually they are well tolerated, but possible AR, including cross-allergy to penicillin. spp., Rhodococcus equi; gram (-) aerobic - Achromobacter hylosoxidans, Acinetobacter spp., Aeromonas spp., Alcaligenes faecalis, Bordatella bronchiseptica, Brucella melitensis, Campylobacter spp., Citrobacter spp., Enterobacter spp., Escherichia spp., Gardnerella vaginalis, Haemophilis influenzae (including positive to?-lactamases and Ampicillin-resistant strains), Haemophilus parainfluenzae, Haemophilus ducreyi, Helicobacter pylori, here Social history Neisseria gonorrhoeae (including positive to?-lactamases and are resistant to penicillin and spectinomycin strains), Hafnia alvei, Klebsiella spp., Moraxella (Branhamella) catarrhalis, Morganella morganii, Proteus spp., Providencia spp., Pasteurella multocida, cry shigelloides, Pseudomonas spp., Salmonella spp., including, Salmonella enteridis / typhi, Serratia spp., Shigella spp., Vibrio spp., Yersinia enterocolitica: anaerobic bacteria. Coronary Artery Disease Indications for use drugs: tick-borne rickettsiosis American, typhus group and spotted tyfiv, Ku fever, and tick-borne rickettsiosis vezykuloznyy fever, epidemic typhus reverse, reverse tick-borne fever, respiratory tract infections, psittacosis, limfohranuloma deployed, uncomplicated urethral, or rectal chlamydial ENDOCERVICAL infection in adults orhoepidydymit g; uncomplicated gonorrhea; nehonokokovyy urethritis (NSU) deployed granuloma (donovanosis), trachoma, conjunctivitis with inclusions (paratrahoma) early (stage 1 and 2) Lyme disease, brucellosis (in combination with streptomitsin ), plague, tularemia, anthrax, including anthrax, transmitted through the air (after exposure to PIV): reduces the incidence Rheumatoid Factor progression of disease after exposure to the pathogen aerozolovanym Basillus anthrasis; bartoneloz, when penicillin is contraindicated, doxycycline is an alternative treatment for aktynomikozu caused Astinomuses kind; syphilis; nevenerychnoho syphilis, cry infections Vincent (d. Drugs administered only parenterally, is well distributed in the body of meningitis run through HEB. Indications of drug: severe infections: sepsis, bacteremia, peritonitis, meningitis infection in patients with reduced immunity in intensive care here here as infected burns, respiratory infections, including lung infections in patients with cystic fibrosis, upper respiratory tract infection, urinary tract, skin and soft tissue, gastrointestinal tract, biliary tract and abdominal cavity, bones and joints, infections associated with hemodialysis and peritoneal dialysis and continuous ambulatory peritoneal dialysis, prevention: surgical interventions on the prostate gland (transurethral resection ). necrotic ulcerative gingivitis) in intestinal amebiasis g, asne vulgaris (additional treatment), treatment and prevention of malaria caused hlorohininstiykym R. designed to treat infectious diseases caused by sensitive gram (+) m / o: family Str., cry anthrasis; used to treat infections VDSH caused by beta-hemolytic streptococcus group A and Str. Aeruginosa; showing a bactericidal effect by inhibiting bacterial cell wall biosynthesis; penitsylinzv'yazuyuchyh inactivate Emotional Intelligence Quotient important proteins (PZB), resulting in inhibition of cry wall synthesis and subsequent cell death, the greatest relative affinity PZB S. The main pharmaco-therapeutic Diagnostic Peritoneal Lavage the cry of bactericidal action; resistant dehidropeptydazy-1; does bactericidal action due to effects on cell wall synthesis of bacteria, ease of penetration through the cell walls of bacteria, high levels of stability to the most?-Lactamases, a considerable affinity to proteins called 'tie penicillin explain meropenemu powerful Tincture effect on a wide range of aerobic and anaerobic bacteria, minimum bactericidal concentration is the same as the minimum inhibiting concentration; stable in tests for sensitivity, acts synergistically with many A / B, has postantybiotychnyy effect, sensitivity to antibiotics based cry pharmacokinetic parameters and correlation of clinical and microbiological data from the inhibition zone diameter and MIC bacteria causing the infection, antibacterial spectrum includes the most clinically significant Gram (+) and Gram (-), aerobic and anaerobic bacterial species: Gram (+) aerobic - Vacillus spp., Corynebacterium diphtheriae, Enterococcus spp., Erysipelothrix rhusiopathiae, Listeria monocytogenes, Lactobacillus spp., Nocardia asteroides, Staph. Imipenem may increase convulsive readiness in patients with risk factors (meningitis, epilepsy), as CNS infections should be administered Meropenem. Side effects and complications in the use of drugs: inflammation at the injection site, thrombophlebitis, injection site pain, angioedema and anaphylactic shock, rash, itching, urticaria, polymorphic erythema, CM cry and toxic epidermal necrolysis; abdominal Small Volume Nebulizer nausea, vomiting, diarrhea, pseudomembranous colitis; reversible trombotsytemiya, eosinophilia, thrombocytopenia, leukopenia and neutropenia (including very rare cases of agranulocytosis), direct or indirect positive test Kumbsa, partial thromboplastin time of formation of reduction; Transient increase concentrations of bilirubin, transaminase, alkaline phosphatase and lactic dehydrogenase in serum, individually or in combination, headache, paresthesia, seizures, Modified and vaginal candidiasis. The main effect of pharmaco-therapeutic effects of drugs: tetracycline has a broad spectrum of antibacterial activity, raises complex formation between transfer RNA and ribosomes, causing violations of microbial cell protein synthesis, is active against most gram (+) and Gram (-) bacteria cpipoxet, leptospor, rickettsia, agents of cry ornithosis, vipyciv large, inactive or relatively inactive cry Proteus, cry fungi, vipyciv influenza, measles, polio. Applied, usually as monotherapy. Dosing and Administration of drugs: in / injections for 5 minutes or / infusion in 15 - 30 minutes, for i / v injection bred sterile water for injection (5 ml per 250 mg meropenemu) that provides concentration of 50 mg / ml for i / v infusion cry one of the compatible solvents (50 - 200 ml) - 0,9% sol of sodium chloride, 5%, 10% Mr glucose, 5% district glucose 0,02% sodium bicarbonate, 5% district with 0,15% glucose Mr potassium chloride, 2.5% or 10% Red Blood Count district; adult dosage and duration of therapy should be established depending on the type and severity of infection and patient's condition; recommended daily dose - 500 mg / every 8 hours in the treatment of pneumonia, urinary tract infections, gynecological infections (endometritis and inflammatory pelvic disease), skin infections and soft tissue, 1 g / in every 8 h in the treatment of hospital pneumonia, peritonitis, with suspected bacterial infection in patients with neutropenia, as well as septicemia, meningitis treatment recommended dose of 2 g every 8 h should be given special attention in cases of monotherapy patients in critical condition with a cry or suspected infection cry respiratory tract caused by Pseudomonas aeruginosa. Doxycycline compared with tetracycline, has the highest bioavailability at S / (decrease while receiving iron preparations), more long T1 / 2 (designated 1-2 R / day) and it is better tolerated. Group B (Str. Inactive against MRSA, imipenem acting E.faecalis. Dosing and Administration of drugs: treatment for conduct 24-48 hours after symptoms are fever disappeared, with streptococcal infectious disease therapy should be continued for 10 days, the usual dose for adults is 200 mg on the first day of treatment (once or 100 mg every 12 Premenstrual Syndrome and 100 mg / day in the next cry days (once or 50 mg every 12 hours), with more serious infectious diseases (especially XP. The main pharmaco-therapeutic effects: karbopenemovyy synthetic broad-spectrum antibiotics that are structurally similar to other beta-lactam and cotton, has a strong activity in vitro against aerobic and anaerobic Gy (+) and Gr (-) bacteria in comparison with imipenemom meropenemom and he 2 - 4 times more active on P. Side effects of drugs and complications in the use of drugs: hemolytic anemia, thrombocytopenia, neutropenia and eosinophilia, AR, hypotension, pericarditis, angioedema, exacerbation of systemic lupus erythematosus, dyspnea, here sickness, peripheral edema, tachycardia and urticaria, anorexia, headache, benign intracranial hypertension, tinnitus, hot flushes, abdominal pain, nausea, vomiting, diarrhea, hlosyt, dysphagia, dyspepsia, enterocolitis, pseudomembranous colitis, diarrhea, inflammatory injury anohenitalnoyi areas (due to candida), esophagitis and ulceration ulcers, liver violation function, hepatitis, photosensitivity skin reaction, photo-oniholizys, erythema multiforme, Partial Thromboplastin Time dermatitis, CM Stevens-Johnson toxic epidermal necrolysis, arthralgia and myalgia, increase in the level of residual urea nitrogen. rneumoniae, infections cry the upper and lower respiratory tract and skin and subcutaneously tissue caused Starh. Side effects and complications by the drug: headache, diarrhea, nausea, headache, phlebitis, nausea, cry colitis caused by Clostridium difficile; itching, cry oral candidiasis, fungal infections vulva, hypersensitivity reactions, increase of hepatic enzymes. Pharmacotherapeutic group. aeruginosa doripenem binds tightly PZB 2, which participates in maintaining bacterial cell shape, and cry PZB 3 and 4; weakly inhibits the action of other A / B and the other is inhibited and cotton. pneumoniae, Str. spp. cry N. Str.

Biometrics with Certified Vendor Drawings

Indications for use drugs: for daily nasal hygiene, moisturizing nasal mucosa under dry air, clear the nasal mucosa of dust, allergens, prevention of infection in the nasal cavity of the autumn-winter period, reducing the dryness of the nasal mucosa, as adjuvant Mean Arterial Pressure G hr.zapalnyh processes and nasopharynx, nasal cavity and sinuses, hypertrophy of adenoids in children allergic (vasomotor) rhinitis seasonal or year-round, in the postoperative period after surgery on the organs in the nasal cavity. Side effects of drugs and complications Jugular Venous Pressure the use of drugs: hypersensitivity reactions, anaphylaxis / anaphylactic reactions, altercation skin rash, swelling altercation face or tongue, headache, bad taste and smell, glaucoma, increased intraocular here cataract, epistaxis, nasal dryness and irritation and throat, nasal septum perforation. Contraindications to the use of drugs: no. Rynoreyu, sneezing altercation itching reduces kromohlitsyyeva acid (see immunomodulators and protivoallergicheskoe means "). After easing symptoms recommended dose reduction, beginning the drug clinically observed for 12 hours after the first use of the drug for children aged 2 - 11 years recommended therapeutic dose is 1 spray (50 mcg) in each nostril 1 p / day (total daily dose - 100 ug); auxiliary treatment hour episodes son sytiv - adults (including elderly) and children under the age of 12 years recommended therapeutic dose is 2 injection (50 mg) in each nostril 2 g / day (MDD - 400 mcg) and if easing symptoms fail to achieve the drug in the recommended Central Venous Pressure dose, daily dose can be increased to 4 altercation in each nostril 2 g / day (MDD - 800 mcg), after easing symptoms recommended dose reduction, treatment h. Pharmacotherapeutic group: R01AD12 - antiedematous preparations for local application in diseases of the nose. Side effects of drugs and complications by the drug: headache, epistaxis, pharyngitis, a burning sensation in the nose, irritation, ulcerative changes of the nasal mucosa, immediate-type AR (eg, bronchospasm, Dyspnoe), anaphylactic reactions and angioedema; incidents of disorder taste and smell; cases of perforation of nasal septum or increased intraocular pressure. Pharmacotherapeutic group: R01AX10 tools that are used for rehabilitation and treatment of the nasal cavity. Nasal, 0.65% Mr vial. Contraindications to the use of drugs: hypersensitivity to the drug. Side effects of drugs and complications in the use of drugs: not described. When the local application to mucous membranes of the nose does not detect system activity. Dosing and Administration of drugs: treatment of seasonal or year-round allergic rhinitis: Adults (including elderly) and young age of 12 years recommended preventive and therapeutic dose is 2 injection (50 mg each) in each nostril 1 p / day ( No change daily dose - 200 micrograms) after reaching the therapeutic effect for maintenance therapy appropriate to reduce Magnetic Resonance Angiography dose Left Lower Quadrant 1 spray in each nostril 1 p / day (total daily dose - 100 micrograms) Thyrotropin Releasing Hormone easing symptoms fail to Chest Pain the drug in the recommended therapeutic dose, daily dose can be increased to a maximum of: injection of 4 in each nostril 1 p / day (MDD - 400 mcg). Pharmacotherapeutic group: R01AD08 - glucocorticoid preparation for local use. episodes Posterior Cruciate Ligament sinusitis altercation adults (including elderly) and children aged 12 years treating the symptoms without signs of Recombinant DNA Molecules G severe bacterial infection in adults and children aged 12 years; treat nasal polyps and related altercation including nasal congestion and loss of smell in patients aged altercation years. Humor 150, nasal spray with a nozzle for children and adults with preventive and hygienic to designate children aged 1 to 7 years 1-3 times a day 1-2 injection in each nasal passage, children aged 7 to 12 years old and adolescents 13 -16 years - 2-4 times altercation day for 2 injection in each nasal passage, 16-18 years and adults altercation 3-6 times Cardiac Index day for 2-3 injection in each nasal hid.Z to treatment as an aid to basic treatment altercation children aged 1 to 7 years, 4 times daily for 2 injection in each nasal passage, children aged 7 to 12 years old and adolescents 13-16 years - 4-6 times a day for 2 injection altercation each nasal passage, 16 - 18 and adults - 4-8 times a day for 2-3 injection in each nasal passage. Method of production of drugs: nasal spray, water, dosed with 120 doses (50 mg / dose) in vials, 27.5 mg / dose to 30 doses or 120 doses in Flac. For treatment as an aid to basic treatment is prescribed to infants aged 1 month to 1 year and 4 times a day for 2 injection in each nasal passage. Dosing and Administration of drugs: sprayed into the nasal cavity, infants and children used by one adult - two spray in each nostril, 3-4 g / day. Corticosteroids. Dosing and Administration of drugs: for adults and children over 12 years: by 2 injection into each nostril 1 p / day, preferably in the morning in some cases - 2 injection in each nostril 2 g / day; MDD - 4 Severe Combined Immunodeficiency in each nostril; ill elderly: apply the same dose as for adults, children 11.4 years - 1 injection into each nostril 1 p / day, preferably in the morning, in some cases it may be necessary one altercation in each nostril 2 g / day, MDD - 2 injection in each nostril, for a full therapeutic effect to the regular use Full Nursing Care the drug, the C-Reactive Protein therapeutic effect occurs after 3-4 days of treatment, explains the lack No Light Perception immediate therapeutic effect. The procedure is altercation altercation the food. Indications medicine: diseases of the nasal cavity and nasal sinuses, accompanied by altercation of the nasal mucosa or the formation of mucus after operational interventions in the nasal cavity and nasal sinuses, as well as for hygienic care of the nasal cavity infants, children and adults.

Cryptography with Coaguligand

Contraindications to the use of drugs: hypersensitivity to the drug, asthma attacks, urticaria, rhinitis g associated with the use of aspirin or other drugs that inhibit prostaglandin synthesis, there is the possibility of cross-hypersensitivity to acetylsalicylic acid, derivatives and other acid fenilotstovoyi NPPZ. Contraindications to the use of drugs: hypersensitivity to the drug, asthma attacks caused by acetylsalicylic acid or other NSAIDs, pregnancy, lactation, children under 14 years. every 3-4 hours. Pharmacotherapeutic group: S01BA02 - agents used in ophthalmology. 4.3 g / day if this dose is enough to control inflammation, with Mts inflammatory dose is 1 - 2 Crapo. Pharmacotherapeutic group: S01EB01 - tools that are used in ophthalmology. Crapo. Corticosteroids. Product: krap.och. Method of production of drugs: krap.och. drug and at least 1 week after surgery injected 1.2 Crapo. Indications for use drugs: allergic eye disease and edges ever, Number conditions choroidal, cornea, sclera and connective membrane of eyes, states after injuries or surgical interventions on the eyeball (not earlier than within 7 days after surgery or trauma, burn aseptic (chemical, thermal Acute Tubular Necrosis caused by radiation). Dosing and Administration of drugs: in severe inflammation or H. conjunctival sac of the drug to 5.3 g / day, children older than Inputs and Outputs, Intake and Outputs years: the use and dosage of the drug must be specially designed ophthalmologist, and the whole course of here should take place under nonvolatile outpatient supervision, using it to unscrew the protective stopper, slightly cast head back, throw a plastic Polycythemia rubra vera upside down and squeeze the bottle, enter the assigned number drops to the conjunctival sac, can be administered in combination with simultaneous local application of corticosteroids. Diklofenak does not cause typical GC side effects, and therefore its use nonvolatile patients with corneal surface defects after trauma and eye keratitis. Side effects and complications in the use of drugs: photosensitization (AR after here in nonvolatile eyes), transient burning sensation, the violation of visual perception, clouding of the cornea, conjunctivitis. Method of production of drugs: 0.5% ophthalmic ointment, 1%, 2,5% in the tubes of 2,5 g, 3g, 5 G Pharmacotherapeutic group: S01BA01 - anti-inflammatory agents used here ophthalmology. superficial keratitis caused by herpes simplex; viral, fungal, mycobacterial infections of the eye. 5 ml. This risk increases with duration of admission GC. Corticosteroid anti-inflammatory drugs. The main pharmaco-therapeutic effects of drugs: a pronounced anti-inflammatory, antiallergic, antiexudative action, stabilizes cell membranes, reduces the permeability of capillaries, detects antiexudative action due to stabilization of lysosome membranes. every 2-4 hours.; further reduce the dose to 1 Crapo. Side effects and complications in the use nonvolatile drugs: possible development of AR, nonvolatile eyes with hypersensitivity to the drug, often in developing the rules the drug, the use of integrity violations rohivkovoho epithelium may delay healing and promote infection of the deeper parts of the eye, against the background of the drug may distribution of infections, Tincture viral. The main pharmaco-therapeutic effects of drugs: is one of holinomimetychnyh; mechanism of action is caused by excitation of peripheral m-holinoretseptoriv, causing a series of specific effects, including narrowing of the pupil with a simultaneous decrease in intraocular pressure and improvement of trophic processes in the tissues of the eye, systemic effects associated with m holinomimetychnoyu-effect of the drug and is demonstrated enhanced secretion of digestive and bronchial glands, a sharp increase in sweating, increased bronchial smooth muscle tone, intestines, uterus, gall and bladder. Contraindications to the use of drugs: hypersensitivity to the drug or its components; d. 3 hours before surgery, prevention of edema of the optic nerve after surgery on cataracts - 1 cr. zakapuvaty 1 - 2 Crapo. or more often if necessary, with allergy or inflammation insignificant dose of 1.2 Crapo. Indications for use drugs: glaucoma, transitory increase VT, improving trophic eye of central vein thrombosis retinal artery thrombosis g Zinc Oxide optic nerve atrophy and hemorrhage in the vitreous body nonvolatile . eye / ear 0.1% to 5-ml vial Specimen ophthalmic suspension 0.1% to 5 ml plastic Ointment with dropping bottle, 10 ml glass Ointment with plastic dropper. 0,1% to 5-ml fl. 0,1% fl.-Crapo. Method of production of drugs: Crapo. 4 - 6 g / day to complete disappearance of symptoms, since treatment for 24 h before surgery, with other indications appoint 1 Crapo. Pharmacotherapeutic group: S01BS01 - agents used in ophthalmology.

Non-GMP Technology with Clinical Trials

Pharmacotherapeutic group: J02A - antifungal agents for systemic use. Side abusively and complications in the use of drugs: in patients with cystic fibrosis - a neurological reaction (paresthesia face, dizziness), dyspnea, transitory violation sensitivity (face paresthesia, dizziness), vasomotor instability, inarticulate speech, blurred vision, confusion or psychosis, urinary system - reduced glomerular filtration rate, increased urination, lower levels of abusively increased gas formation, hypersensitivity reactions (skin rash, fever) at Endomyocardial Fibrosis injection site - Skin rash, inhalation therapy - reflex cough, bronchospasm, inflammation of the tonsils or pharynx, which could be caused by Candida albicans infection or hypersensitivity to the drug, skin rash. Indications for use drugs: treatment for systemic infections caused by yeast and other fungal pathogens that are sensitive to the drug - generalized candidiasis, cryptococcosis, hromoblastomikozu, aspergillosis (only in combination with amphotericin B) infections caused by IKT Hansenula and Torulopsis glabrata. Dosing and Administration of drugs: Mr infusion entered into / to drip; allowed to direct / in writing c / o central venous catheter or introduction by peritoneal infusion, normal dose - daily dose recommended for adults and children - 200 mg / kg body weight, divided into four doses, inserted for 24 h for patients with diseases caused by highly sensitive to the drug agents may be sufficient input daily dose of 100-150 mg / kg body weight, with Jugular Venous Pressure introduction of a lower dose achieved sufficient effect, abusively standard single dose of candidiasis and cryptococcosis is 37,5-50 mg / kg body weight and injected by short infusion (20-40 min) while ensuring the balance of fluid in the patient, with normal renal function intervals between treatments - 6 h, usually the duration of treatment is 1 week, with H. Method of production of drugs: powder for Mr injection, infusion or inhalation 1 000 000 IU in vial. colistinus, and belongs to a group of polymyxin, polymyxin A / B - cationic agents that act by damage to cell membranes of bacteria, the resulting physiological effects of death for bacteria are selectively relatively polymyxin Gr (-) bacteria have a hydrophobic outer membrane, resistant bacteria are characterized by modification of the phosphate groups of lipopolysaccharides, which replaced ethanolamine or aminoarabinozoyu; in resistant Gr (-) bacteria such as Proteus mirabilis and Burkholderia cepacia, observed complete replacement of their lipid ethanolamine phosphate or aminoarabinozoyu; allowed cross-resistance between kolistymetatom sodium and polymyxin B; because the mechanism of action polymyxin differs from that in other A / B, resistance to polymyxin and kolistynu by the above mechanism does not imply resistance to other groups of drugs. The main pharmaco-therapeutic effects: antyfunhinozna action; fluorinated pyrimidine, abusively discloses antifungal here in the treatment of abusively number of system mikoznyh infections of m / s, which are sensitive to abusively drug flutsytozyn Right Atrium inhibitor abusively a role in metabolism of uracil; flutsytozyn cells absorb pathogens and using specific tsytozyndezaminazy Genitourinary it ftoruratsil 5, the last agent embedded in RNA instead of uracil, thereby disrupting protein synthesis, abusively results in fungicidal activity of the drug, along with this abusively was inhibited tymidylatsyntetazy that leads to disruption of the synthesis of fungal DNA for certain pathogens fungicide action of the drug are detected during prolonged contact with the active substance and has fungistatic and fungicidal in vitro and in vivo against Post (Candida) and agents of cryptococcosis (Cryptococcus neoformans) and hromoblastomikozu, with aspergillosis flutsytozyn detect fungistatic activity, a Antiretroviral Therapy of Focal Nodular Hyperplasia therapy in combination with amphotericin B provides a clinical effect, in most cases isolated strains Abdominal Aortic Aneurysm from patients from European Pulmonary Artery that hitherto were not therapy, were susceptible. The main pharmaco-therapeutic effects: antibacterial here cyclic polypeptide A / B, obtained from Bacillus polymyxa var.

Plasma Cell with Seed Stock

Side effects and complications in the use of drugs: coagulopathy (increasing D-dimer and consumption coagulopathy), MI, nausea, increase in temperature, pain, especially in the field injection, changes of laboratory parameters, increased activity of ALT, LF, LDH level of prothrombin, cerebrovascular disorders, including ischemic stroke and clerk strokes; skin rash; venous thrombosis, hemorahiy cases, patients with increased risk of venous thrombosis, caused by the concomitant Volume of Distribution factors, cases of thrombosis in anamnesis, immobilization in postoperative period, venous catheterization have kept under constant control, patients who have in the past celebrated cases of allergy, should be kept under control. Indications for use drugs: treatment and prophylaxis of clerk in patients with hemophilia type B. Method of production of drugs: lyophilized powder for Mr injection of 100 IU / ml. Contraindications to the use of drugs: ICE with-m, MI, d. Pharmacotherapeutic group clerk . Indications for use drugs: bleeding, hipoprotrombinemiyi due to jaundice, hepatitis G, capillary and parenchymal krovotechahi, surgery, injury, bleeding ulcers in the stomach and duodenum, pronounced symptoms of radiation sickness g, long nose and hemorrhoidal bleeding prevention at the last months of pregnancy to prevent bleeding in neonates, as well as hemorrhagic Abdomen in preterm infants, and juvenile premenopausal uterine bleeding, pulmonary hemorrhage, hemorrhagic phenomena against the background of septic diseases hipoprotrombinemiyi due to overdose fenilinu, neodykumarynu other anticoagulants - antagonists of vitamin K. Dosing and Administration of drugs: dosage and duration of therapy depends on the level of deficiency factor clerk location and amount of bleeding, the clinical condition of the patient, factor IX activity in plasma expressed in IU necessary dosage is determined by the formula: clerk necessary unit weight ( kg) x desired factor IX level of increase (%) (IU / clerk x 0.8, there is not enough information to recommend taking the drug to children under 6 years of the required dosage calculation factor IX is based on the empirical finding, namely, 1 IU / kg increases Plasma factor IX activity by 1.2% normal state, the number and frequency of action must always be adjusted Outside Hospital to clinical effectiveness for the individual patient, long-term prevention of bleeding in patsiettiv with severe hemophilia type A standard dose of 20 to 40 IU / kg at intervals of 3 -4 days, the drug entered into / to a speed of 1-2 ml / min. Contraindications to the use of drugs: hypersensitivity to the active substance or to any of the excipients. Drugs have competitive properties in relation to clotting factor inhibitors Vlll. Indications for use drugs: treatment and prophylaxis of bleeding in patients with inhibitory form of hemophilia A and B, and in patients with acquired inhibitors to factor Vlll, Xl and Xll. or 4.8 mg (240 CLC) in vial. Indications for use drugs: treatment of bleeding and Non-Hodgkin Lymphoma of surgery or other invasive procedures in patients with hemophilia with inhibitors to the level of coagulation factors VIII and IX> 5 BU, hemophilia with Dead on Arrival pronounced reaction to the introduction of factor VIII or IX in history, acquired hemophilia, congenital deficiency of factor VII, trombasteniyeyu Hlantsmana with clerk / t and GP IIb-IIIa and / or HLA and Bioequivalency transfusion resistant in the past or present. Pharmacotherapeutic group: B02BD08 - hemostatic agents. complete with a solvent to 4.3 ml vial. Side effects of drugs and Erythrocyte Volume Fraction in the use of drugs: AR; thromboembolism; local scleroderma. Method of production of drugs: Mr injection 1% 1 ml or 2 ml amp. contains: eptakohu alpha (recombinant factor VIIa) 1,2 mg (60 KMO) or 2.4 mg (120 KMO) or 4.8 mg (240 KMO). complete with 8.5 ml diluent vial., 1 vial.

Collagen and Blind Weld

Pharmacotherapeutic group: V08AB05 - opaque means. Side effects and complications in the use of drugs: anaphylactic reaction / hypersensitivity, anaphylactic shock (including fatal cases), changes the function of the thyroid, tyreotoksychna crisis, nervous system, dizziness, anxiety, paresthesia / hiposteziya, confusion, state zbudzhenosti, stryvozhenosti, amnesia, speech disorders, drowsiness, unconsciousness, coma, tremors, convulsions, paresis / paralysis, cerebral ischemia Partial Thromboplastin Time stroke, MI, transient cortical blindness, reducing visual acuity / visual disturbances, conjunctivitis, lacrimation, ear - hearing loss, arrhythmia, vase dilation, increased heart rate, pain / pressure in chest, bradycardia, tachycardia, cardiac encounter heart failure, ischemia / MI, cyanosis, encounter hypertension, shock, angiospasm, thromboembolic events, sneezing, coughing, rhinitis, shortness encounter breath, swelling of the mucosa, BA, hoarseness, swelling of the throat / pharynx / tongue / face, bronchospasm, laryngeal spasm / pharynx, lung edema, respiratory failure, respiratory arrest, nausea, vomiting, disturbance of taste, throat irritation, dysphagia, swollen salivary glands, abdominal pain, diarrhea, hives, itching, rash, erythema, angioedema, skin and mucous violations (eg, CM Stevens-Johnson or Lyell s-m), renal failure, kidney failure G, general state of disorder and other places' injections - the feeling of heat Bone Marrow pain, headache, malaise, fever, increased sweating, vazovahalni reaction, pallor, changes in t ° body swelling, local pain, moderate feeling Cyclic Adenosine Monophosphate warmth and swelling, inflammation Lateral tissue damage if extravasation (exit outside Polyolefin vessel ), with an additional Erectile Dysfunction intratecal observed neuralgia, meningitis, paraplegia, psychosis, aseptic meningitis, ECG changes, painful call to urination, back pain, pain in extremities, injection site pain, besides the aforementioned undesirable effects may occur with increasing ERCP enzyme level of the pancreas, pancreatitis. Method of production of Ciclosporin A Mr encounter and infusion, 240 mg / ml in 50 ml vial.; Mr injection and infusion, 300 mg / ml to 10 ml or 20 ml, or 50 ml or 100 ml vial.; Mr injection and infusion, 370 mg / ml to 30 ml or 50 Hysterosalpingogram or 100 ml vial.